Actinium Pharmaceuticals Lawsuit: A Critical Analysis for Impacted Investors

The recent class action lawsuit against Actinium Pharmaceuticals, Inc. (NYSE: ATNM) has sent shockwaves through the biotech sector, particularly for investors who held the stock between October 31, 2022, and August 2, 2024. Filed on May 6, 2025, by the prominent firm Levi & Korsinsky, LLP, the case alleges that the company engaged in securities fraud by misrepresenting the viability of its lead drug candidate, Iomab-B, and its chances of FDA approval. This article examines the lawsuit’s claims, its implications for investors, and the critical steps affected shareholders must take to seek recovery.

The Allegations: A Breakdown of the Lawsuit

The lawsuit centers on Actinium’s conduct during the development and reporting of its Phase 3 Sierra trial for Iomab-B, a treatment for relapsed/refractory acute myeloid leukemia (AML). The complaint outlines four key areas of alleged misconduct:

1. Misleading Statements on FDA Approval Prospects:
   The company is accused of overstating the likelihood of the Sierra trial data meeting FDA guidelines for a Biologics License Application (BLA). Investors were allegedly led to believe that the trial’s results were sufficient for approval, when in reality, the data fell short.

2. Manipulation of Survival Data:
   Actinium provided additional analyses, including long-term follow-ups, to mitigate poor Overall Survival (OS) data from the Sierra Trial. The lawsuit claims these analyses were inadequate and did not address the FDA’s concerns, further misleading investors.

3. Ignoring FDA Risks:
   Despite internal warnings about the FDA’s skepticism toward the BLA’s current form, the company allegedly downplayed these risks. The lawsuit argues that the FDA would likely refuse to review or approve Iomab-B as submitted.

4. Inflated Business Prospects:
   The complaint asserts that the company’s positive statements about its business and financial prospects were “materially misleading” and lacked a reasonable basis, constituting violations of federal securities laws.

Stock Performance During the Class Period

To understand the financial impact on investors, a review of ATNM’s stock price is critical. would likely show significant volatility, with potential declines coinciding with FDA updates or trial data disclosures. Investors who bought during this period may have suffered losses due to the alleged misrepresentations.

Legal Deadlines and Investor Action

The lawsuit’s success hinges on investor participation. The lead plaintiff deadline is May 27, 2025, meaning affected shareholders must act swiftly to request lead plaintiff status. Notably, participation incurs no out-of-pocket costs, as Levi & Korsinsky operates on a contingency fee basis. Even investors who do not serve as lead plaintiffs may be eligible for compensation if the case succeeds.

Why This Lawsuit Matters

Levi & Korsinsky, LLP—a firm with a 20-year history of recovering over $10 billion for shareholders—has a strong track record. Its representation in high-profile cases, such as the Theranos and Purdue Pharma litigations, underscores its credibility. For Actinium, the lawsuit could force transparency about Iomab-B’s regulatory hurdles and hold executives accountable for alleged misstatements.

Conclusion: Navigating the Path Forward

The Actinium lawsuit highlights the risks of investing in biotech firms with late-stage clinical trials. For investors who lost money during the class period, joining the lawsuit is a logical step to seek recovery. Key takeaways include:
- Timing is critical: The May 27 deadline leaves little room for delay.
- No financial risk: Participation requires no upfront costs.
- Historical precedent: Levi & Korsinsky’s success in similar cases suggests a credible path to recovery.

While the FDA’s final decision on Iomab-B remains uncertain, the lawsuit underscores the importance of due diligence in biotech investments. For those affected, leveraging legal recourse is not just a right—it’s a strategic move to mitigate losses in an industry where regulatory outcomes can make or break a stock’s value.

Investors are urged to consult with the firm immediately to preserve their rights and explore compensation options. The stakes are high, but with the right legal support, recovery is within reach.